Fintel reports that on December 4, 2025, Needham initiated coverage of Solid Biosciences (NasdaqGS:SLDB) with a Buy recommendation.
Analyst Price Forecast Suggests 198.07% Upside
As of November 17, 2025, the average one-year price target for Solid Biosciences is $15.47/share. The forecasts range from a low of $9.09 to a high of $21.00. The average price target represents an increase of 198.07% from its latest reported closing price of $5.19 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Solid Biosciences is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -3.03.
What is the Fund Sentiment?
There are 238 funds or institutions reporting positions in Solid Biosciences. This is an increase of 6 owner(s) or 2.59% in the last quarter. Average portfolio weight of all funds dedicated to SLDB is 0.10%, an increase of 9.23%. Total shares owned by institutions decreased in the last three months by 0.31% to 85,851K shares. 
The put/call ratio of SLDB is 0.24, indicating a bullish outlook.
What are Other Shareholders Doing?
Perceptive Advisors holds 11,834K shares representing 15.19% ownership of the company. In its prior filing, the firm reported owning 11,907K shares , representing a decrease of 0.62%. The firm decreased its portfolio allocation in SLDB by 1.93% over the last quarter.
Bain Capital Life Sciences Investors holds 7,912K shares representing 10.15% ownership of the company. No change in the last quarter.
Siren, L.L.C. holds 7,416K shares representing 9.52% ownership of the company. No change in the last quarter.
Ra Capital Management holds 5,811K shares representing 7.46% ownership of the company. In its prior filing, the firm reported owning 5,811K shares , representing an increase of 0.00%. The firm decreased its portfolio allocation in SLDB by 7.99% over the last quarter.
Adage Capital Partners Gp, L.l.c. holds 4,000K shares representing 5.13% ownership of the company. In its prior filing, the firm reported owning 6,729K shares , representing a decrease of 68.24%. The firm decreased its portfolio allocation in SLDB by 29.22% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
